TNFRSF17 and Miyoshi myopathy: Bispecifics in clinical development are principally targeting BCMA, but other targets are being explored, such as the GPRC5D protein with an anti GPR5D/CD3 bispecific, which showed clinical in vitro activity for MM [48].